Teladoc Health, Inc. (NYSE:TDOC) Receives Consensus Rating of “Hold” from Brokerages

Shares of Teladoc Health, Inc. (NYSE:TDOCGet Free Report) have received a consensus rating of “Hold” from the twenty-one ratings firms that are currently covering the firm, MarketBeat reports. Fourteen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $12.24.

Several brokerages have issued reports on TDOC. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price target on shares of Teladoc Health in a research report on Tuesday, August 20th. Evercore ISI upped their price objective on shares of Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Teladoc Health from $10.00 to $12.00 and gave the stock a “hold” rating in a research report on Friday, November 1st. Royal Bank of Canada boosted their price target on shares of Teladoc Health from $9.00 to $10.00 and gave the company an “outperform” rating in a research report on Wednesday, October 9th. Finally, TD Cowen cut their price objective on shares of Teladoc Health from $9.00 to $8.00 and set a “hold” rating for the company in a report on Thursday, October 31st.

Check Out Our Latest Report on TDOC

Insider Transactions at Teladoc Health

In other news, Director Thomas Mckinley bought 4,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $7.69 per share, for a total transaction of $30,760.00. Following the completion of the acquisition, the director now owns 39,077 shares in the company, valued at approximately $300,502.13. This trade represents a 11.40 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Carlos Nueno sold 2,389 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $11.93, for a total value of $28,500.77. Following the completion of the sale, the insider now directly owns 2,890 shares in the company, valued at $34,477.70. The trade was a 45.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TDOC. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Teladoc Health by 15.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,701,161 shares of the health services provider’s stock worth $15,617,000 after acquiring an additional 228,004 shares during the period. Clearline Capital LP boosted its position in shares of Teladoc Health by 395.6% during the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after purchasing an additional 3,483,665 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Teladoc Health by 195.3% in the second quarter. The Manufacturers Life Insurance Company now owns 95,307 shares of the health services provider’s stock worth $932,000 after purchasing an additional 63,028 shares during the period. Jennison Associates LLC bought a new position in Teladoc Health in the third quarter worth $1,544,000. Finally, Massachusetts Financial Services Co. MA lifted its position in Teladoc Health by 477.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 370,093 shares of the health services provider’s stock valued at $3,397,000 after buying an additional 305,961 shares during the period. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Stock Up 1.9 %

Teladoc Health stock opened at $11.00 on Friday. Teladoc Health has a fifty-two week low of $6.76 and a fifty-two week high of $22.54. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73. The firm’s 50-day simple moving average is $9.63 and its 200 day simple moving average is $9.20. The stock has a market cap of $1.89 billion, a PE ratio of -1.91 and a beta of 0.97.

Teladoc Health (NYSE:TDOCGet Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.10. The business had revenue of $640.51 million for the quarter, compared to analyst estimates of $630.50 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. Research analysts predict that Teladoc Health will post -1.16 EPS for the current fiscal year.

Teladoc Health Company Profile

(Get Free Report

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

Read More

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.